{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-26-009157","form_type":"8-K","ticker":"ALLR","cik":"0001860657","company_name":"Allarity Therapeutics, Inc.","filed_at":"2026-01-29T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.588844+00:00","generated_at":"2026-05-16T06:33:59.110514+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Allarity Therapeutics enters $6M equity line of credit with Tumim Stone Capital","bullets":["Company may sell up to $6M of common stock at 95-97% of VWAP discount.","Commitment fee of $45,000 paid to investor upon execution.","Shares subject to Exchange Cap (19.99% of outstanding) unless stockholder waiver obtained.","Company must seek stockholder approval at next annual meeting to waive Exchange Cap.","Investor cannot own more than 4.99% (or 9.99% at its election) of outstanding shares."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-009157","json":"https://secwatch.observer/filing/0001213900-26-009157.json","markdown":"https://secwatch.observer/filing/0001213900-26-009157.md","text":"https://secwatch.observer/filing/0001213900-26-009157.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1860657/000121390026009157/0001213900-26-009157-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1860657/000121390026009157/ea0274173-8k_allarity.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T06:33:59.110514+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"79e99846e0d6378aa9855ab8e166572516012638","claim":"Allarity Therapeutics, Inc. entered into Common Stock Purchase Agreement with Tumim Stone Capital LLC (effective 2026-01-28).","evidence_excerpt":"On January 28, 2026, Allarity Therapeutics, Inc. (the “ Company ”) entered into a Common Stock Purchase Agreement (the “ Purchase Agreement ”) with Tumim Stone Capital LLC, a Delaware limited liability company (the “ Investor ”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1860657/000121390026009157/0001213900-26-009157-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"Tumim Stone Capital LLC"},{"label":"Effective","value":"2026-01-28"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}